• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The hypotensive response to hydralazine, in triple therapy, is not related to acetylator phenotype.三联疗法中，肼屈嗪引起的降压反应与乙酰化代谢表型无关。
Br J Clin Pharmacol. 1982 May;13(5):747-50. doi: 10.1111/j.1365-2125.1982.tb01452.x.
2
Plasma concentration and acetylator phenotype determine response to oral hydralazine.
Hypertension. 1981 Sep-Oct;3(5):580-5. doi: 10.1161/01.hyp.3.5.580.
3
Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?在为高血压患者开肼屈嗪处方时，是否应该确定乙酰化代谢表型？
Eur J Clin Pharmacol. 1984;26(1):39-42. doi: 10.1007/BF00546706.
4
Influence of acetylator phenotype and renal function on the antihypertensive effect of hydralazine.乙酰化代谢表型和肾功能对肼屈嗪降压效果的影响。
Neth J Med. 1984;27(3):69-73.
5
Determinants of response to intravenous hydralazine in hypertension.高血压患者静脉注射肼屈嗪反应的决定因素
Clin Pharmacol Ther. 1981 Dec;30(6):773-81. doi: 10.1038/clpt.1981.237.
6
The effects of oral hydralazine on blood pressure, cardiac output and peripheral resistance with respect to dose, age and acetylator status.口服肼苯哒嗪对血压、心输出量及外周阻力的影响，涉及剂量、年龄和乙酰化状态。
Radiother Oncol. 1990 Aug;18(4):293-8. doi: 10.1016/0167-8140(90)90109-a.
7
Synthesis, formulation, and clinical pharmacological evaluation of hydralazine pyruvic acid hydrazone in two healthy volunteers.
J Pharm Sci. 1985 Feb;74(2):193-6. doi: 10.1002/jps.2600740218.
8
Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.NAT2基因的不同表型影响顽固性高血压患者的肼屈嗪降压反应。
Pharmacogenomics. 2014 Feb;15(2):169-78. doi: 10.2217/pgs.13.202.
9
Relationship between the genetically determined acetylator phenotype and DNA damage induced by hydralazine and 2-aminofluorene in cultured rabbit hepatocytes.在培养的兔肝细胞中，遗传决定的乙酰化酶表型与肼屈嗪和2-氨基芴诱导的DNA损伤之间的关系。
Proc Natl Acad Sci U S A. 1982 Feb;79(4):1269-72. doi: 10.1073/pnas.79.4.1269.
10
The effect of intense treatment with hypotensive drugs on structural design of the resistance vessels in spontaneously hypertensive rats.
Acta Physiol Scand. 1971 Oct;83(2):280-2. doi: 10.1111/j.1748-1716.1971.tb05078.x.

引用本文的文献

1
Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?在为高血压患者开肼屈嗪处方时，是否应该确定乙酰化代谢表型？
Eur J Clin Pharmacol. 1984;26(1):39-42. doi: 10.1007/BF00546706.
2
Genetically determined variability in acetylation and oxidation. Therapeutic implications.乙酰化和氧化的基因决定变异性。治疗意义。
Drugs. 1985 Apr;29(4):342-75. doi: 10.2165/00003495-198529040-00003.

本文引用的文献

1
Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method.
Eur J Clin Pharmacol. 1980 Feb;17(2):129-33. doi: 10.1007/BF00562621.
2
The polymorphic acetylation of dapsone in man.氨苯砜在人体内的多态性乙酰化作用。
Clin Pharmacol Ther. 1971 Mar-Apr;12(2):225-38. doi: 10.1002/cpt1971122part1225.
3
Relation of hydralazine plasma concentration to dosage and hypotensive action.肼屈嗪血浆浓度与剂量及降压作用的关系。
Clin Pharmacol Ther. 1972 May-Jun;13(3):420-5. doi: 10.1002/cpt1972133420.
4
Hydralazine slow-release: observations on serum profile and clinical efficacy in man.缓释肼屈嗪：人体血清特征及临床疗效观察
Curr Ther Res Clin Exp. 1977 Feb;21(2):157-68.
5
Hydrallazine with beta-blocker and diuretic in the treatment of hypertension. A double-blind crossover study.肼屈嗪联合β受体阻滞剂及利尿剂治疗高血压。一项双盲交叉研究。
Med J Aust. 1979 Oct 20;2(8):439-40.
6
Hydrallazine and beta-blockade in refractory hypertension with characterization of acetylator phenotype.肼屈嗪与β受体阻滞剂治疗难治性高血压并对乙酰化表型进行特征分析
Aust N Z J Med. 1975 Dec;5(6):530-6. doi: 10.1111/j.1445-5994.1975.tb03857.x.

The hypotensive response to hydralazine, in triple therapy, is not related to acetylator phenotype.

作者信息

Vandenburg M J, Wright P, Holmes J, Rogers H J, Ahmad R A

出版信息

Br J Clin Pharmacol. 1982 May;13(5):747-50. doi: 10.1111/j.1365-2125.1982.tb01452.x.

DOI:10.1111/j.1365-2125.1982.tb01452.x
PMID:7082547
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1402085/
Abstract
摘要